European Journal of Clinical Pharmacology

, Volume 14, Issue 2, pp 105–109 | Cite as

Initial clinical experience of lorcainide (Ro 13-1042), a new antiarrhythmic agent

  • G. Cocco
  • C. Strozzi
Originals

Summary

Lorcainide is a promising antiarrhythmic agent that belongs to the class of local anesthetics. It was tested in 7 patients with malignant ventricular arrhythmias that were resistant to other antiarrhythmic agents. Lorcainide was effective in all cases (complete disappearance of arrhythmias in 6 cases and more than 50% disappearance in the 7th case), and the tolerance was within acceptable limits. The drug was effective at rest, as assessed by 24-h dynamic electrocardiographic monitoring, and during physical exercise. Longer studies with more patients are warranted, since the drug appears to be a promising antiarrhythmic agent.

Key words

Lorcainide antiarrhythmic agent ventricular arrhythmia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dreifus, L. S., Ogawa, S.: Editorial. Quality of the ideal antiarrhythmic agent. Am. J. Cardiol.39, 466–468 (1977)Google Scholar
  2. 2.
    Lown, B., Temte, J. V., Arter, W. J.: Ventricular tachyarrhythmias: clinical aspects. Circulation47, 1364–1381 (1973)Google Scholar
  3. 3.
    Lown, B.: New concepts and approaches to sudden cardiac death. Schweiz. Med. Wochenschr.106, 1522–1531 (1976)Google Scholar
  4. 4.
    Åstrand, I.: Aerobic work capacity of man and woman with specific reference to age. Acta Physiol. Scand.49 (Supp. 169), 1–92 (1960)Google Scholar
  5. 5.
    Lown, B., Wolf, M.: Approaches to sudden death from coronary heart disease. Circulation44, 130–142 (1971)Google Scholar
  6. 6.
    Corday, E.: Introduction to the Symposium on identification and management of the candidate for sudden cardiac death. Am. J. Cardiol.39, 813–815 (1977)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • G. Cocco
    • 1
    • 2
  • C. Strozzi
    • 1
  1. 1.Institute of General Medical Clinics and Medical TherapeuticsUniversity of FerraraItaly
  2. 2.Hoffmann-La Roche & Co. Ltd.BasleSwitzerland

Personalised recommendations